Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Tuesday, Nov. 25, 2025 at 4:30 p.m. ET

CALL PARTICIPANTS

  • President and CEO — Christopher Anzalone
  • Chief Medical Officer and Head of R&D — James Hamilton
  • Outgoing Chief Medical Officer and Advisor — Bruce Given
  • Chief Commercial Officer — Andy Davis
  • Chief Financial Officer — Daniel J. Apel

Need a quote from a Motley Fool analyst? Email [email protected]

TAKEAWAYS

  • Rodemplo FDA Approval -- The FDA approved Rodemplo as the first siRNA therapy and first medicine specifically indicated for familial chylomicronemia syndrome (FCS), with the drug entering distribution channels one week post-approval.
  • Rodemplo Label and Safety -- The approved label lists no contraindications, warnings, or precautions; most common adverse reactions are hyperglycemia, headache, nausea, and injection site reactions.
  • Rodemplo Clinical Results -- In the PALISADE phase III study, Rodemplo achieved "deep and durable reductions in median triglycerides as early as one month," with overall reductions around 80% from baseline and sustained levels below 500 mg/dL throughout one year.
  • Pancreatitis Outcomes -- Combined analysis of 25 mg and 50 mg Rodemplo doses showed statistically significant reduction in adjudicated acute pancreatitis events compared to placebo.
  • Pricing Model -- The "one Rodemplo" pricing model sets a uniform annual WAC price of $60,000 per patient, regardless of indication, with early positive feedback from payers.
  • Patient Population Estimates -- Management estimates approximately 6,500 FCS patients in the US and identifies a broader potential US population of 750,000 with persistent chylomicronemia at risk for acute pancreatitis.
  • Phase III Program Status -- Enrollment completed in Shasta 3, Shasta 4, and MIRROR III phase III trials, totaling about 2,150 patients; top-line data expected second half of 2026 with regulatory submissions planned by year-end 2026.
  • Shasta 5 Trial Update -- The Shasta 5 study was recently broadened in design to include a more generalizable persistent chylomicronemia/high-risk pancreatitis population, and is currently enrolling.
  • Zodasiran (Yosemite Trial) -- First subject dosed in phase III Yosemite trial for homozygous familial hypercholesterolemia (HoFH); full enrollment projected in 2026 and potential NDA filing by end of 2027.
  • Dual-Target RNAi (Aerodimer PA) -- Regulatory clearance filed to initiate phase III for Aerodimer PA, a dual PCSK9/APOC3 RNAi therapy in mixed hyperlipidemia targeting a US population estimated at 20 million.
  • CNS Pipeline Advancement -- CTA filed for phase III trial of ARO MAPT for tauopathies, leveraging proprietary delivery technology enabling blood-brain barrier penetration and>75% MAPT mRNA knockdown in preclinical models.
  • Obesity Program Progress -- Two obesity drug candidates (ARO Inhibin E and ARO ALK7) have together randomized 192 patients; initial safety and biomarker data expected January 2026, with more comprehensive data by end of 2026.
  • Sarepta Collaboration Milestones -- $200 million milestone payment earned following protocol-based progress in ARO DM1; follows a prior $100 million milestone earned for the first prespecified enrollment target.
  • Novartis Collaboration -- Announced a global license and collaboration for Arrow SNCA (preclinical siRNA for Parkinson’s), including a $200 million upfront payment, future potential milestones up to $2 billion, and royalties up to low double digits.
  • Full-Year 2025 Financials -- Reported fiscal year 2025 net loss of $2 million ($0.01/share), a sharp improvement from a $599 million net loss in 2024; revenue reached $829 million driven entirely by licensing and collaborations.
  • Revenue Composition -- Of $829 million revenue, $697 million came from Sarepta (including $587 million recognition of initial consideration, $94 million for milestone, and $16 million in reimbursements), $130 million from Sanofi, and $2.6 million from GSK.
  • Operating Expenses -- Operating expenses totaled $731 million in fiscal year 2025, up $126 million year-over-year, driven by late-stage clinical trial costs (notably for posasiran and SHTG) and commercialization activities for Rodemplo.
  • Operating Cash Flow -- Net cash provided by operating activities reached $180 million in fiscal year 2025, a $643 million positive swing from prior year, primarily due to receipts from collaborations.
  • Cash Position -- Cash, investments, and available-for-sale securities totaled $919 million as of September 30, 2025, compared with $681 million the prior year, primarily reflecting collaboration inflows.
  • Share Count Change -- Common shares outstanding at period-end were 135.7 million, down 2.4 million sequentially due to repurchase of shares from Sarepta.
  • Future Capital Inflows -- Closed $200 million Novartis upfront payment and earned second $200 million Sarepta milestone (to be received in January 2026), both not fully reflected in period-end figures.
  • Cash Runway Statement -- Management stated that the company’s cash runway extends into fiscal 2028, even without additional deal inflows, while supporting both commercial and clinical development plans.
  • Guidance on Commercial Sales Impact -- Management does not anticipate commercial sales of Rodemplo to have a substantial financial impact in fiscal year 2026.

SUMMARY

The FDA approval and prompt launch of Rodemplo mark Arrowhead Pharmaceuticals, Inc. (ARWR +5.72%)’s transition into a commercial-stage company and introduce the first approved siRNA therapy for FCS. Multiple late-stage trials for label expansion of Rodemplo have reached full enrollment, and results are expected to enable regulatory filings by year-end 2026. Business development milestones materially improved the balance sheet, notably a $200 million Novartis upfront for Arrow SNCA and another $200 million earned from Sarepta, with the company’s cash and investments rising to $919 million. Arrowhead’s management forecasts that existing cash resources are sufficient to fund all current development and commercialization efforts through 2028 without requiring additional external capital. No detailed forward financial guidance was provided, and management cautions that early Rodemplo commercial sales will not meaningfully impact near-term financials.

  • Rodemplo’s commercial launch deployed a single, uniform pricing model across current and future indications, removing disease-specific pricing disparities.
  • Double-digit million patient populations are targeted in the pipeline by next-in-line programs, including Aerodimer PA and ARO MAPT, advancing toward pivotal trials in cardiometabolic and CNS indications.
  • Late-stage pipeline expansion and rapid clinical progress contrast with last year’s deep net loss, with net loss for 2025 nearly eliminated due to revenue from strategic partnering.
  • Management emphasized that share count declined, attributing the reduction to Sarepta share repurchases rather than equity dilution.
  • The Shasta 5 design was broadened to include more representative SHTG patients at high risk for pancreatitis, with enrollment underway and acute pancreatitis reduction as the primary endpoint.
  • Revenue is highly concentrated among partners, with the Sarepta agreement comprising approximately 84% of total reported revenue for the period.
  • Key 2026 readouts will include initial obesity data, evidence from the dual-target Aerodimer PA program, and results from multiple late-stage studies in severe hypertriglyceridemia.

INDUSTRY GLOSSARY

  • siRNA (small interfering RNA): A therapeutic modality that uses short RNA molecules to silence disease-causing genes by targeted degradation of specific mRNA.
  • FCS (Familial Chylomicronemia Syndrome): A rare genetic disorder characterized by extremely high triglyceride levels and increased risk of pancreatitis.
  • WAC (Wholesale Acquisition Cost): The manufacturer’s list price for a drug to wholesalers, before discounts or rebates.
  • TRiM platform: Arrowhead Pharmaceuticals’ proprietary delivery technology designed to improve the targeting and potency of RNAi therapeutics.
  • Shasta/Mirror Studies: Arrowhead Pharmaceuticals’ key late-stage clinical trial programs evaluating posasiran (Rodemplo) across FCS and related metabolic populations.
  • PALISADE Study: The pivotal phase III clinical trial for Rodemplo in FCS, forming the basis for FDA approval.
  • PCSK9/APOC3: Genes targeted in lipid-modifying therapies; inhibition leads to reductions in LDL cholesterol and triglycerides, respectively.
  • sNDA (Supplemental New Drug Application): A regulatory submission seeking approval for new indications, dosing, or labeling for an existing approved drug.
  • HoFH (Homozygous Familial Hypercholesterolemia): A rare genetic disorder resulting in markedly elevated LDL cholesterol from birth, leading to early cardiovascular disease.
  • Mixed Hyperlipidemia: A lipid disorder involving elevation of both LDL cholesterol and triglycerides, increasing cardiovascular disease risk.
  • MAPT: The gene encoding tau protein; targeted in Arrowhead’s CNS pipeline for tauopathies such as Alzheimer’s disease.
  • SHTG: Severe hypertriglyceridemia, characterized by fasting triglycerides above a threshold associated with increased pancreatitis risk.
  • Acute pancreatitis: Sudden inflammation of the pancreas; high triglyceride levels confer increased risk, and event rates are a clinical trial endpoint.
  • CSF (Cerebrospinal Fluid): The fluid surrounding the brain and spinal cord; used in biomarker assays for CNS-targeted therapies.

Full Conference Call Transcript

Christopher Anzalone, President and CEO of the company.

Christopher Anzalone: Thanks, Vince. Good afternoon, everyone, and thank you for joining us today. Before we begin, I'd like to announce that this will be Bruce Given's final earnings call. He's been a valuable member of the Arrowhead Pharmaceuticals team for almost fifteen years. He will continue to help Arrowhead Pharmaceuticals as a trusted adviser, but now that Rodemplo has received its first FDA approval, he will be stepping back from day-to-day operational responsibilities and, hopefully, he can finally enjoy his time in retirement. Or his reretirement, which is probably more accurate. His contributions to Arrowhead Pharmaceuticals' success, both current and future, have been critical, and we owe him a heartfelt thank you.

Later in the call, you will hear from Bruce, who will discuss the Rodemplo FDA approval when he came back to Arrowhead Pharmaceuticals and out of retirement to help us get across the finish line. Bruce leaves us in a strong position with a very strong group of leaders across the organization. As you all know, James Hamilton has already assumed much of Bruce's prior responsibilities as Chief Medical Officer and Head of R&D. So thank you again, Bruce, for getting us to today. Thank you, James, for taking us into the next chapter for Arrowhead Pharmaceuticals. Let's now turn to our business and what progress we've made during the recent period.

This has been a very busy and enormously productive last few months. The most impactful change is the FDA approval of Rodemplo. On November 18, we announced that the FDA approved Rodemplo, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome or FCS. FCS is a severe, rare disease with an estimated 6,500 people in the United States living with genetic or clinical FCS characterized by triglyceride levels that can be ten to 100 times higher than normal, leading to a substantially higher risk of developing acute recurrent, potentially fatal pancreatitis. This is Arrowhead Pharmaceuticals' first FDA-approved medicine, marking a major milestone for the company as it transitions into a commercial stage.

Rodemplo is the first and only FDA-approved siRNA medicine for people living with FCS and can be self-administered at home with a simple subcutaneous injection once every three months. Rodemplo is the first and only FDA-approved medicine to be backed by adequate well-controlled studies that include patients with genetically diagnosed and clinically diagnosed FCS. After many months of preparation, our commercial team was able to hit the ground running, and I'm happy to report that we have the drug in the channel a mere week after approval. We also launched Reliant Rodemplo, a patient support program providing support services and resources for patients at each stage of the treatment journey with Rodemplo, including financial assistance options for eligible patients.

In addition, we also announced the one Rodemplo pricing model that creates one consistent price across current and potential future indications. This is important. We are committed to sustainable innovation. This requires rational drug pricing according to the value a medicine offers to patients and healthcare systems. It also means that we will not ask different patients to pay different amounts for the same drug based solely on what disease they've been diagnosed with. Rodemplo is a pancreatitis drug, and when we think about pricing, we look to those patient populations who are at greatest risk of acute TG-related pancreatitis. The patients we are serving now are also those at greatest risk of pancreatitis, people with FCS.

This includes those with a defined set of mutations as well as those who share the same level of chylomicronemia symptoms but with more heterogeneous and often less well-characterized genetic backgrounds, who we refer to as clinically defined or phenotypic FCS. The broader patient population would substantially increase the risk of acute pancreatitis for those with persistent chylomicronemia, meaning fasting triglycerides greater than 880 milligrams per deciliter. We believe there are approximately 750,000 of these patients in the US, and while they often have less day-to-day symptoms than FCS patients, they are clearly at high risk for acute pancreatitis.

The one Rodemplo pricing model has these patients in mind, and the $60,000 annual WAC price is designed to provide real value to patients and healthcare systems in this population. Our Shasta 3 and Shasta 4 phase three studies are designed to support an sNDA in this population, and while those studies are ongoing and we are actively serving the FCS population, we will have time to help payers properly appreciate Rodemplo's value, and payers will have time to plan and budget for its possible eventual adoption and regulatory review and approval. Outside of Rodemplo, we have also made good progress with two other pipeline programs in the cardiometabolic space.

Zidaziran, aerodimer PA. Let's start with zodasiran. During the recent period, we dosed the first subject in the Yosemite Phase three clinical trial of zidaziran. Our clinical candidate is being developed as a potential treatment for homozygous familial hypercholesterolemia, or HoFH. HoFH is a rare genetic condition that leads to severely elevated LDL cholesterol and early onset cardiovascular disease. Yosemite will enroll approximately sixty subjects over the age of 12, who will be randomized to receive four doses once every three months of two hundred milligrams of Adasiran or placebo. The primary endpoint is the percent change from baseline to month twelve in fasting LDL C.

The phase two data in this patient population were encouraging, and we hope to have this study fully enrolled in 2026, complete the study in 2027, and if successful, enable an NDA filing by the end of 2027 and launching in 2028. The next new pipeline program in cardiometabolic is Aerodimer PA. During the last quarter, we filed a request for regulatory clearance to initiate a Phase III clinical trial of Airodyma PA, being developed as a potential treatment for atherosclerotic cardiovascular disease or ASCVD, due to mixed hyperlipidemia, in which both LDL cholesterol and triglycerides are elevated. This is a very large population without proper treatment options.

We believe there are approximately twenty million people in The US with mixed hyperlipidemia. Airdymer PA is a dual-function RNAi therapeutic designed to silence the expression of the PCSK9 and APOC3 genes in the liver, designed to reduce both LDL C and TGs. This represents an important step forward for the RNAi field as we believe it is the first clinical candidate to target two genes simultaneously in one molecule and an important step forward for preventative cardiology as both LDL and TGs have epidemiologic support as being important drivers of ASCVD risk. Both these programs fit well strategically with our growing commercial focus on the cardiometabolic space and on the physicians that treat these patients.

Also during the quarter, we expanded our clinical pipeline in CNS. We filed a CTA to initiate a Phase III clinical trial of ARO MAPT as a potential treatment for tauopathies, including Alzheimer's disease. ARO MAPT is Arrowhead Pharmaceuticals' first therapy to utilize a new proprietary delivery system, which in preclinical studies has achieved blood-brain barrier penetration and deep knockdown of target genes across the CNS, including deep brain regions, after subcutaneous injections. Nonclinical evaluations in monkeys with subcutaneous administration of ARO MAPT using clinically translatable doses have shown better than 75% knockdown of the tissue level of MAPT mRNA in CNS.

Importantly, monkey tissue level knockdown has translated into CSF tau protein reductions with a duration of effect supportive of either monthly or quarterly subcutaneous dose readiness. This is an exciting program, and we look forward to initiating the study shortly. We also continue to make good progress on our first two obesity programs.

ARO I and HBE, and ARO AP seven. Together, we have randomized one hundred and ninety-two patients, all with a BMI greater than thirty. Because we started ARO I and HBE earlier, it is about two quarters further into the phase one study than ARO ALC7. Our plan has been to share early data at the end of the year, but due to travel schedules and the holidays, this will push a couple of weeks later into the early part of 2026. We also expect to have more fulsome data toward the end of 2026. We also made important progress in business development.

First, as we announced yesterday, we earned a $200 million milestone payment from Sarepta following a drug safety committee review and subsequent authorization to dose escalate, and achievement of the second prespecified patient enrollment target for ARO DM1. This follows a $100 million milestone earned previously when Arrowhead Pharmaceuticals reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a phase one two clinical study of ARO DM1. This partnership continues to be productive, and we look forward to continued progress.

In addition to progress on the constructive partnership, we announced a new global licensing collaboration agreement with Novartis for Arrow SNCA, Arrowhead Pharmaceuticals' preclinical stage siRNA therapy against alpha synuclein for the treatment of Parkinson's disease. The collaboration includes a limited number of additional targets outside our pipeline that will utilize Arrowhead Pharmaceuticals' proprietary TRiM platform. Arrowhead Pharmaceuticals received a $200 million upfront payment from Novartis and is also eligible to receive development, regulatory, and sales milestone payments of up to $2 billion. Arrowhead Pharmaceuticals is further eligible to receive tiered royalties on commercial sales up to low double digits. As I mentioned before, the recent approval of Rodemplo is clearly the most important recent development.

Arrowhead Pharmaceuticals has been busy across the pipeline and in business developments during the recent period. Business development and licensing are critical to our business model, and we are pleased to have these two significant deals closed this year. With that overview, I'd now like to turn the call over to Bruce Given.

Bruce Given: Thanks, Chris. Good afternoon, everyone. I'm happy to give my final update to Arrowhead Pharmaceuticals shareholders at such an important time and with Arrowhead Pharmaceuticals in such a position of strength. We have built something truly unique and powerful at Arrowhead Pharmaceuticals, and with the first FDA approval behind us, it feels like the right time for me to step back and retire. So let's review some of the key parts of the recent FDA approval that we announced last week. Mostly, I'll discuss the label and information contained in the packaged insert. Rodemplo is approved as an adjunct to diet to reduce triglycerides in adults with FCS.

The recommended dose of Rodemplo is twenty-five milligrams, and it can be self-administered at home by subcutaneous injection once every three months. Rodemplo has no contraindications, warnings, or precautions. The most common adverse reactions include hyperglycemia, headache, nausea, and injection site reactions. The FDA submission was supported by clinical data from the phase three PALISADE study in patients with both genetic FCS and those with the same clinical manifestations of disease but without solely a genetic cause, referred to as clinically diagnosed FCS. The blinded portion of the trial compared a year of therapy with Rodemplo or placebo dosed every three months and tested two doses of posasiran versus placebo.

The primary endpoint was the change in median triglycerides at month ten. There were also multiplicity-controlled secondary endpoints, all of which were statistically significant, including notably the occurrence of acute pancreatitis, for which the twenty-five and fifty-milligram doses were combined for comparison to placebo as called for in the analysis plan. Posasiran achieved deep and durable reductions in median triglycerides as early as one month when the first measurement was taken. Overall, these reductions were around eighty percent from baseline, and reductions largely maintained median triglyceride levels below the usual guideline-directed threshold of five hundred milligrams per deciliter throughout the year of treatment.

Five hundred milligrams per deciliter is the recognized threshold where the risk of pancreatitis increases relative to a normal population. Importantly, patients with genetic FCS versus clinical FCS showed similar reductions from baseline. We see the clinical FCS population as having the same high unmet need as the genetic FCS group, and as such, we think it is crucial to have shown that both patient populations showed similar large reductions from baseline triglycerides with Rodemplo therapy. Posasiran is also labeled as having reduced the rate of adjudicated pancreatitis events versus placebo, a very welcome finding for FCS patients and their caregivers and an important validation that reductions in triglycerides can, in fact, lead to reductions in pancreatitis.

Let me close by saying that it's gratifying to have been a part of Arrowhead Pharmaceuticals from the early days of our siRNA developments and part of the posasiran program at its inception and again over the last several years. And more importantly, it's exciting to hear the enthusiasm about this new medicine from patients, caregivers, and physicians. I'd also like to wish all of you an enjoyable Thanksgiving holiday. I'll now turn the call over to Andy Davis.

Andy Davis: Thank you, Bruce. It's been exactly one week since the launch of Rodemplo, and the early feedback we've received from healthcare professionals, patient societies, and payers has been very encouraging. We hear lots of enthusiasm about the differentiating attributes of Rodemplo, which generally fall into five value pillars, some of which the team has touched on briefly already. First, the reduction in triglycerides is both significant and sustained. In PALISADE, Rodemplo reduced triglycerides by an unprecedented minus 80% from baseline as early as month one and maintained this marked reduction with minimal variation throughout the full twelve-month treatment period. This compared to a minus 17% reduction in the pooled placebo group.

With Rodemplo, patients now have real hope, many for the first time, of achieving triglyceride levels below guideline-directed risk thresholds associated with acute pancreatitis, such as five hundred milligrams per deciliter. In Palisade, fifty percent of patients at the twenty-five milligram dose achieved TG levels below five hundred milligrams per deciliter, with approximately seventy-five percent achieving levels below eight hundred and eighty milligrams per deciliter at month ten. Second, the numerical incidence of acute pancreatitis in patients treated with Rodemplo was lower compared with placebo. As we all know, this is the outcome of most importance for healthcare professionals, patients, and payers. Third, Rodemplo demonstrated favorable safety and tolerability.

Importantly, the US-approved package insert contains no contraindications, no warnings, and no precautions associated with the use of Rodemplo. Fourth, Rodemplo can be self-administered at home with a simple subcutaneous injection once every three months, just four injections per year. Physicians tell us this infrequent dosing schedule is likely to reduce the treatment burden on physicians, patients, and caregivers. And fifth, early feedback on the one Rodemplo pricing model has been positive. As Chris highlighted, this model creates one consistent price of $60,000 per patient per year across current and potential future indications such as severe hypertriglyceridemia.

Again, this means that we will not ask different patients to pay different amounts for the same drug based solely on what disease they have. We have been in important discussions with payers, and early signs for market access are encouraging. As a reminder, we believe there are an estimated 6,500 people in the US living with genetic or clinical FCS, and the prescriber base comprises specialist physicians such as lipidologists, endocrinologists, preventive cardiologists, and internal medicine physicians with a focus on lipid disorders. These specialists often operate within multidisciplinary teams that may include gastroenterologists, advanced practice providers, and specialized dietitians. At launch, we are targeting approximately 5,000 healthcare professionals through personal engagement.

And finally, our rely on Rodemplo patient support program is operational and designed to make every step of the journey easier. This program is designed to assist patients and physicians with insurance verification, financial assistance options, a first dose starter kit, and supplemental injection training. We launched just one week ago, but our care coordinators are already actively processing Rodemplo start forms, conducting patient welcome calls, and engaging payers to obtain approvals. And as Chris stated, we're happy to announce that we already have the drug available in the channel ahead of schedule. I will now turn the call over to James Hamilton to discuss the broader R&D portfolio.

James Hamilton: Thank you, Andy. I'd like to give a quick review of the status of our late-stage Phase III studies and also describe the design of a couple of our early-stage programs. Let's start with the suite of Phase III studies of posasiran designed to potentially support a supplemental NDA filing to expand the label beyond genetic and clinical FCS. Shasta 3 and Shasta 4 are Phase III studies designed to compare reductions in triglycerides with twenty-five milligrams of posasiran compared with placebo over twelve months of treatment. Between the two studies, we enrolled approximately 750 patients. In addition, the MIRROR III study enrolled approximately 1,400 patients.

This study in patients with mixed hyperlipidemia is designed to supplement the safety database we file the sNDA for posasiran in severe hypertriglyceridemia. We are not planning to seek approval in the mixed hyperlipidemia patient population. We completed enrollment in the global Shasta-three and Shasta-four as well as MIRROR three Phase three clinical studies in June 2025. We anticipate completing the primary portions of these studies in mid-2026 with top-line data expected in the second half of 2026. If successful, we plan to make submissions before the end of 2026 for regulatory review and potential approval.

The SHTG program also features a study named Shasta five to directly assess the ability of posasiran to reduce the risk of acute pancreatitis as the primary endpoint in SHTG patients at high risk of acute pancreatitis. We are currently enrolling patients in that study. Of note, we will also be assessing pancreatitis risk reduction in Shasta three and Shasta four as a key secondary endpoint, but Shasta five is the first event-driven study to assess acute pancreatitis as the primary endpoint. I would also like to provide an update on our obesity programs ARO Inhibit E and ARO ALK seven. Both of these programs target the known active impact that is involved in signaling to adipocytes to store fat.

ARO inhibin E inhibits one of the ligands in the pathway, and ARO ALK7 inhibits the receptor on the adipocyte that these ligands bind. So essentially, we are trying to reduce the message sent to store fat and the way the message is received at the end of the service. ARO inhibin E started enrolling patients in December 2024, and ARO ALK7 initiated in May 2025. Both programs are currently in phase one 2a, first-in-human dose-escalating studies to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics. Both programs include Part one, designed to assess single and multiple doses as monotherapy, and part two designed to assess multiple doses in combination with other therapies.

As ARO inhibin E started about two quarters earlier, we have more mature data in that study. The study is nearly fully enrolled, and we are on schedule and currently planning to share initial data from this program around the middle of 2026. This is a rather robust first-in-man study that is collecting multiple measures of drug activity and pathway activity, and we are eager to share initial findings. We were originally planning on sharing the first data around the end of the year, but due to the holidays and travel, January worked best for all schedules. For ARO ALK7, we intend to provide a brief snapshot of early safety and target engagement results from that study.

Both targets have strong genetic validation, and both programs have yielded promising results in preclinical studies. So it will be interesting to see similarities and differences in patient response in the clinical trials. I will now turn the call over to Dan Appel.

Daniel J. Apel: Thank you, James, and good afternoon, everyone. I'll provide a brief outline of our financial results. As we reported today, our net loss for fiscal year 2025 was $2 million for a loss of $0.01 per share, based on 133.8 million fully diluted weighted average shares outstanding. This near breakeven result compares with a net loss of approximately $599 million for a loss of $5 per share based on 119.8 million fully diluted weighted average shares outstanding in fiscal year 2024. Revenue for fiscal year 2025 totaled $829 million and was driven entirely by our license and collaboration agreements with Sarepta, Sanofi, and GSK. Of the $829 million, roughly $697 million pertain to the Sarepta arrangement.

Of that $697 million, $587 million relates to the ongoing recognition of initial surrender consideration, $94 million relates to the achievement of the first EM-one milestone, and $16 million relates to the reimbursement of incurred collaboration program costs. Additionally, the license to Sanofi for Greater China rights to plazosin contributed $130 million to our fiscal 2025 revenue. And lastly, to round things out, we recorded $2.6 million earlier in the year related to a milestone payment under the GSK HBV agreement. Turning to expenses, total operating expenses for fiscal year 2025 were approximately $731 million compared to $605 million for fiscal 2024, an increase of $126 million.

The year-over-year increase was driven by $101 million of higher R&D expenses and $25 million of higher SG&A, both of which I will explain in brief. The key drivers of research and development spend included costs to run our clinical trials, our clinical manufacturing costs, as well as expenses related to active programs in the preclinical stage. 2025 R&D costs were heavily impacted by our phase three clinical trials for posasiran and SHTG. It's worth noting that in fiscal year 2025, nearly two-thirds of our clinical trial spend can be attributed to the late-stage development of posasiran and SHTG. As we have mentioned, the SHTG registration studies are now fully enrolled, and we expect data to read out next year.

Accordingly, the majority of remaining Phase III registration clinical trial costs are expected to occur over the next twelve months. Our SG&A costs increased by $25 million year-over-year, driven primarily by our preparations for the commercialization of Rodemplo. All of us here at Arrowhead Pharmaceuticals are enormously proud of the capabilities we have built to commercialize Rodemplo, not only in our commercial functions but also across regulatory, supply chain, order to cash, and indeed across all of our enabling support functions.

Turning now to cash flow, net cash provided by operating activities during fiscal year 2025 was $180 million, compared with net cash used in operating activities of $463 million in the prior year, for a net positive change year-over-year of $643 million. This increase in cash from operating activities is driven by cash received from licensing and collaboration agreements, partially offset by the aforementioned increase in R&D and SG&A costs. Turning to the balance sheet, our cash and investments, including available-for-sale securities, totaled $919 million as of September 30, 2025, compared to $681 million as of September 30, 2024.

The increase in our cash and investments was primarily related to our licensing and collaboration agreements with Sarepta, Sanofi, and GSK, partly offset by our ongoing cash burn. Our common shares outstanding as of the end of the quarter were 135.7 million, down 2.4 million from the prior quarter due mainly to the repurchase of shares from Sarepta. I'll use this opportunity to reiterate two developments that are subsequent to the fiscal year and leading up to today, which were financially meaningful for Arrowhead Pharmaceuticals and our balance sheet.

Firstly, as Chris mentioned earlier on the call, we announced a licensing and collaboration agreement with Novartis for ARO SMTA, Arrowhead Pharmaceuticals' preclinical stage siRNA targeting alpha-synuclein for the treatment of synucleinopathies, such as Parkinson's disease. Novartis will also be eligible to select a limited number of additional collaboration targets outside of Arrowhead Pharmaceuticals' current pipeline to be developed using our proprietary TRiM platform. The closing occurred last month, and we have already received $200 million in the bank as an upfront payment. As a reminder, we are also eligible to receive up to $2 billion in future milestone payments from Novartis as well as royalties on commercial sales.

Secondly, just yesterday, we announced we earned our second development milestone under the Sarepta collaboration agreement for LL DM1. As Chris mentioned, this triggered a $200 million obligation from Sarepta that will be recorded in 2026, and we expect to receive the cash in January of 2026. This is, of course, additional to the $100 million earned for the first year one milestone in fiscal quarter four of 2025.

Finally, we are not providing detailed financial guidance at this time for the coming fiscal year, beyond reiterating that, while we view the launch of Rodemplo as a truly transformational event for the company, we do not anticipate that the commercial sales of Rodemplo will have a substantial impact on our financial statements in fiscal year 2026. We also believe our cash runway, even in the absence of any further capital from new deals or other sources, and all the while funding a broad ambitious set of commercial clinical programs, to be sufficient to extend into fiscal year 2028. With that, I will now turn the call back to Chris.

Christopher Anzalone: Thanks, Dan. Arrowhead Pharmaceuticals has been working to bring important medicines to patients in need for over fifteen years. As Bruce mentioned, it's very gratifying to see Rodemplo approved by the FDA and the overwhelmingly encouraging feedback we received from the FCS community. But Rodemplo is just one part of a large pipeline we've created to help potentially millions of patients in a diverse set of disease areas. We spent years building the TRiM platform to enable us to bring RNAi where it is needed. We are now able to address seven different cell types and have current clinical programs in five of these.

Further, we will meet our twenty in twenty-five goal whereby we will have 20 individual drug candidates in clinical trials by the end of this year. Our partnering has been helpful but judicious, with approximately half of our clinical pipeline wholly owned and half partnered. We have late-stage studies ongoing, again, both independently and with partners, that may potentially lead to multiple new commercial launches over the next few years. In addition, we have a strong financial position that enables us to properly invest in our growth today and in the future. We believe we now have everything we need to be in the next class of large and ultimately profitable biotech companies.

Thanks for joining us today, and I would now like to open the call to your questions. Operator?

Operator: Thank you. To ask a question, please press 11 on your telephone and wait for your name to be announced. To withdraw your question, please press 11 again. And we ask that you please limit yourself to one question. One moment, please. Our first question comes from the line of Luca Issy with RBC Capital Markets.

Luca Issy: Bruce, congrats on your reretirement, I should say. So all the best in the next chapter. And then maybe if I can stick with you, can you just maybe talk about what's the plan to show in terms of acute pancreatitis for posasiran? Are you confident just the three and four in Q3 2026 can actually hit acute pancreatitis? Or is the base case scenario, those two trials, are maybe underpowered to show benefit and you actually need Shasta five to actually hit on acute pancreatitis given the positive death population is enriched for history of acute pancreatitis.

The only reason why I'm asking is it looks like you doubled the size of the n, I should say, in the Shasta five trial according to clinicaltrials.gov. As of Monday last week. So, again, any call there, much appreciated. Thanks so much.

Bruce Given: Well, I sure will. And, you know, thank you for your kind regards. Shasta three and four were powered on the basis of triglyceride reduction, which is the primary endpoint. So, you know, we did not specifically power Shasta three and four for pancreatitis. However, it was on our mind, and as was also done in the core studies, you know, there is the intent and by design, the capability to pool both Shasta three and four for evaluating versus placebo on reduction of pancreatitis, and, of course, we only have one dose of posasiran, instead of two doses, you know, two different doses like we had, for instance, in the phase two program.

So, you know, there's, I would say, reasonably good power for, you know, for seeing a difference in acute pancreatitis. But we're not dependent on it because we've designed Shasta five specifically to, obviously, be able to have a primary endpoint of acute pancreatitis. We did change the design of it in Shasta five recently to make it a more generalizable population in patients with persistent chylomicronemia and a history of pancreatitis. The original design was a much more enriched population, but it would have actually been less representative than, you know, the duly designed trial.

So it's not so much a matter that we've been powered so much as we, you know, broadened the power of the patient population to be more inclusive of the high-risk population in SHTG. So, you know, we certainly we oftentimes refer to it as a belts and suspenders approach. You know, there's a, you know, obviously, a decent chance that we will show statistical significance in the Shasta three and four programs, but we're not entirely dependent on that because of Shasta five, which is a, you know, study. The first of its kind specifically designed to demonstrate a benefit versus placebo in acute pancreatitis.

Luca Issy: Got it. Thanks so much. Congrats again.

Operator: Thank you. One moment, please. Our next question comes from the line of Prakhar Agrawal with Cantor Fitzgerald.

Prakhar Agrawal: Hi. Thank you for taking my questions and congrats on the quarter as well as the update throughout the quarter. Maybe on the obesity side, I had a couple of questions. So on ARO inhibin E for the update early next year, if you can just provide more details on how much data will be disclosed, especially on the MAD side. And how much follow-up will you have on inhibin E for both monotherapy and combo cohorts? And also the same question on ALK7. What cohorts will be disclosed and will there be any weight loss data at all from ARO ALK7 early in the year? Thank you so much.

James Hamilton: Yeah. Sure, Prakhar. This is James. I can cover that. So for inhibin E, it's a little bit ahead, as Chris mentioned, probably by a couple of quarters. So the study is nearly fully enrolled. We have a good amount of data in both the SAD and MAD healthy volunteer or obese healthy volunteer cohorts. So we'll have biomarker data, MRI data, and as well as safety in those cohorts. And then the combo cohorts are almost fully enrolled.

I think we're waiting on a few more diabetic patients to enroll in the highest dose combo cohorts and should have probably not through the end of the study, but ample post-dose follow-up in both the diabetic and the nondiabetic cohorts from inhibin E. And then ALK7 will be a little bit more limited, focused mostly on monotherapy safety and knockdown data, knockdown of the target for that study.

Christopher Anzalone: Yeah. And keep in mind here that we want to present data that are interpretable, and we're not going to have all cohorts. We're not going to have all patient data in all cohorts even if they're fully enrolled. We don't get data in real-time necessarily. So you'll have probably two bites of the apple, maybe three bites, but certainly two bites of the apple. You know, our goal here is this first round of data is to give you an idea about how these are going. And then, you know, the fuller story should come out once we have the more wholesome datasets in later '26.

Prakhar Agrawal: Got it. Thank you so much.

Operator: You're welcome. Thank you. Our next question comes from the line of Maury Raycroft with Jefferies.

Maury Raycroft: Hi, thanks for taking my question and congrats on the progress and best wishes, Bruce, in retirement. I was gonna ask a follow-up to Luca's question earlier. We're expecting to see the patient baseline profile for your SHTG pivotal next week. What are your estimates on AP events to accrual based on your patient's baseline characteristics? And also your change in plans to broaden the AP adjudication criteria.

Bruce Given: You know, Maury, I think it's a little bit hard to answer just because we have adapted our protocols now to go ahead and adapt the modified Atlanta criteria, you know, since those have been accepted by both FDA and EMA, and here in the US, at least payers. And this is really gonna be our first experience with using that particular scale, which makes it a little hard to estimate exactly how many events we will have. So it's hard to say what you will see next week is you will see the percentage of patients that had a history of pancreatitis that were enrolled in the study.

And, you know, based on that, you know, that, I think you'll see that, you know, there's a good chance that we'll have, you know, the necessary number of events. But I'm a little bit uncomfortable trying to give any real prediction when we're using a scale that we haven't used before.

Maury Raycroft: Understood. That's helpful. Thanks for taking my question.

Bruce Given: Thanks, Maury.

Operator: Thank you. And our next question comes from the line of Jason Gerberry with Bank of America.

Gina: Hi. This is Gina on for Jason. Congrats on all the progress this quarter, and thank you so much for taking part in the question. Just a couple from us. I guess, first on your ARO MAPT program, maybe just discuss which aspects of the drug are maybe differentiated from A and J's recently failed anti-tau antibody and what kind of still gives you the confidence in the target after the failure. And then it's kind of based on your current cash position and the progress that you've made on these partner milestone triggers. Do you have any updates on your visibility on launching a CVOT study?

Is that more tied to kind of seeing how the FCS and central SHTG launches are progressing? And then can you just remind us, like, any potential milestone triggers from the Sarepta programs that you're expecting in 2026? Thank you so much.

Christopher Anzalone: Alright. I count three questions. James, want to take the first one?

James Hamilton: Sure. Yeah. I'll take the first one on the MAPT program. So the J and J antibody, the monoclonal as well as other monoclonals, are, you know, IV administrated monoclonal antibodies. Probably a small fraction of those molecules cross the blood-brain barrier and then are primarily focused on binding to that extracellular tau. So tau that's been released from damaged cells or has been secreted and that can propagate and bind to tau that's outside of the cell. Our approach is very different. We use a targeting ligand to facilitate delivery of the siRNA across the blood-brain barrier into the neuron to silence the expression of tau.

So we're sort of turning off the faucet for all of the expression and preventing the neurofibrillary tangles to form in the first place. We should get that over time be able to reduce the level of intracellular tau and extracellular tau, whereas the monoclonal antibodies are really just able to get the extracellular tau. So that's the key differentiator.

Christopher Anzalone: And on the other two questions, I'll answer the last one first. Sarepta milestones. So we are eligible to receive the first of $550 million annuities in February. So we expect that over the next several months. That's correct. February. Right, Dan?

Daniel J. Apel: Yes. Correct.

Christopher Anzalone: On the visibility on the CVOT. So that CVOT, as you know, is for the dimer. That's a big opportunity for us. And so we are moving as quickly as we can to that CVOT. We'll have a good idea, I think, this summer if we have a drug. You know, we'll know PCSK9 knockdown. We'll know APOC3 knockdown. We'll know LDL decreases. We'll know triglyceride decreases. And so given what those data look like, I think, again, as early as this summer, I think we'll know if we have something that really could be an important treatment for these mixed hyperlipidemia patients. Should that be successful? Should that look good?

We are not waiting on anything, you know, to start those studies other than finishing this phase one two. Our plan is to be able to roll directly into pivotal studies after these phase one, two studies. Again, should they all go well and there's nothing gating there other than the data looking good. We also are hoping to have parallel pivotal studies. You know, one that will be a CVOT and then one that will be looking at simply lowering LDL over the course of the year. As you know, that has been an approval endpoint in the past for PCSK9 inhibitors.

And we think that could be a good way to get to market very quickly and, frankly, help us to pay for the CVOTs. So that's our plan now. We'll have a much better idea about how quickly we can move in the summertime once we start to see data. We're really looking forward to seeing those data.

Gina: Thank you.

Operator: You're welcome. Thank you. And our next question comes from the line of Edward Tenthoff with Piper Sandler.

Edward Tenthoff: Great. Thank you very much. And Bruce, wishing you all the best, and James, wishing you all the best of luck. It really is a super exciting time for the company. I wanted to get a sense just with respect to upcoming data readouts next year, specifically asking, do you think you'll have your first look from the AeroDimer PA next year? And what other datasets beyond the obesity data in the first half should we be thinking about?

Christopher Anzalone: Thanks, Ted. We have a bunch of, I think, potentially very interesting data readouts throughout 2026. As you mentioned, obesity will be the first. You know, as I mentioned, we should have two bites of an apple or thereabouts, and we'll have our first early dataset, you know, in January. And then as the data mature in both those programs, stay towards, you know, the end of the second quarter or something around then, we'll have a much larger dataset. We think those are important. In the summertime, we expect to have dimer data. I think those are extraordinarily important.

You know, the idea that we might have a drug candidate that can simultaneously lower LDL and triglycerides to treat twenty million or so people in the United States with mixed hyperlipidemia is a very exciting opportunity. And, again, we'll I think we'll know if we have something that could really fit there in the summertime. Also in the summertime, I think we'll have our first bit of ARO MAPT data. And we'll be looking for tau levels in the CSF. That also would be extraordinarily exciting. We could be sitting on one of the most exciting potential Alzheimer's drugs in the clinic. And, hopefully, we'll be derisking the entire blood-brain barrier platform.

That can enable us to treat a variety of CNS diseases. So that's an important readout. Of course, also in the third quarter or so, we expect to have the readout for Shasta three and four. Yep. You know, that are designed to enable the sNDA by the end of the year. And then, of course, at the end of the year, we expect to file our sNDA. So look, there will be other, I mean, other things happening during the year, but, you know, those to me, feel like the primary ones. And, of course, we'll be in the market.

You'll be in the market and, you know, we will be really looking forward to seeing the adoption curve that Rodemplo is gonna have.

Edward Tenthoff: Great. Any update on ARO RAGE just to be comprehensive? Thank you.

Christopher Anzalone: Yeah. Thank you. Yes. So as you know, Ted, the data so far for ARO RAGE have been enticing. You know, we've seen that we can knock down RAGE deeply. Both looking at circulating biomarkers as well as valve. You know, that's super interesting. Where we've struggled is looking for biomarkers to show potential clinical benefit. And so rather than running directly into a large asthma or COPD phase two, we were hoping to have a baby step to see some evidence of that. So we have started a challenge study. Don't expect to have data in '26, maybe at the very end of '26, but we've just started that.

And so my hope is that will show us that knocking down RAGE is an important thing. Look. It's been an undruggable target for some time, and now we can drug it. So now let's see what that does for us. I think at the end of that, we can then ask ourselves, do we want to build out a pulmonary franchise or do we want to partner that? And I think a positive challenge study readout would allow us to partner that under attractive terms.

Edward Tenthoff: Great. Well, guys, congrats on all the great progress. I'm really excited to see the Rodemplo launch. It's a great job.

Christopher Anzalone: Thank you, Ted.

Operator: Thank you. Our next question comes from the line of Mani Foroohar with Leerink Partners.

Mani Foroohar: Yes. Thanks for taking the question. Congrats on the progress in the first product launch. And best wishes also to Bruce on his re-retirement. So something tells me you're gonna pop up again soon. I don't think you're done with us. Apropos of the question, can I want to follow up on sort of broader pipeline? I know Ted touched on new ARO RAGE study, etcetera. How do we think about ARO Dimer application in terms of pursuing CVOT, the right target for that technology? And where are the right places for you to put that to work? Now that you've got sort of a very different place in terms of your balance sheet?

Bruce Given: I'm happy to take that. You know, obviously, we're excited about the class around and APOC3 inhibition. Generally, for patients with severe hypertriglyceridemia, you know, that's been a essentially very, very poorly treated population, you know, for a long time. You know, LDL, you know, the LDL side of the equation, on the other hand, has been really a different story. And other than HoFH, you know, there's a pretty good number of tools in the tool chest for dealing with LDL. You know, the patients on that LDL side of the equation, patients with heterozygous familial hypercholesterolemia, which is, you know, a pretty good-sized population, for instance.

But the twenty-some million patients in the US alone that have mixed hyperlipidemia has been an interesting population. You know, we could address the LDL part, but we've done really a terrible job historically of being able to address the triglyceride piece of that. And, you know, the post hoc analyses that have been done of CVOT have shown that for the same LDL reduction, you can really rank order the risk, you know, that patients have by how high their triglycerides are. And, of course, the Mendelian randomization data has also said that triglycerides are an independent predictor of events and mortality in that mixed hyperlipidemia population is huge. It's a very big population.

So, you know, there's never really been a very good way of addressing, you know, both sides of the problem in mixed hyperlipidemia, both the LDL and the triglycerides. And here we're talking about a drug that could potentially do it with a single, you know, say, injection, you know, get, you know, both their LDL and their triglycerides, probably on top of the statins. I think you're gonna always have a statin there if the patients could tolerate it. But you could have a daily statin and a quarterly dimer injection, and that's and potentially, you know, treat, you know, that twenty million patients, you know, to low-risk levels of LDL and triglycerides.

That would be, you know, quite an amazing opportunity, I think, from a marketing perspective. Compared to what you can do today, which is you can probably get the LDL taken care of today, but you probably can't do much at all, you know, worthwhile in the triglycerides. So this is what makes this, you know, to us, such an interesting proposition.

Christopher Anzalone: Yeah. As you know, Mani, what we used to former strategy was to make with us right now or Rodemplo, you know, a three-step drug. Step one is FCS. Step two is FHCG. Step three after a CVOT would be this, you know, would be to be part of a treatment in mixed hyperlipidemia. Once we were able to perfect, at least in animals, the dimer platform, it didn't make any sense any longer. You know, we like the idea of keeping Rodemplo as a pure play pancreatitis drug. Full stop. And now I think we'll have a tool to more completely treat that mixed hyperlipidemia population should this dimer translate well from animals to humans.

Mani Foroohar: That's helpful. And as a follow-up, when you think about potential dimer applications, etcetera, how are you thinking about the data next year from Horizon and how and potentially applications of combining what hopefully will be a validated APOC3 target with other approaches to their risk-elevating elements of the lipid profile?

James Hamilton: Yeah. Sure. So of course, our siRNA is targeting LPA is partnered with Amgen. So we would have to work with them on, you know, any kind of dimer applications. But there are other applications beyond, of course, the PCSK9, APOC3. I mean, we're looking at other dimers in the CV space. Both targeting the hepatocytes and extrahepatic cell types. So, this is probably not the only dimer that you'll see out of Arrowhead Pharmaceuticals.

Mani Foroohar: Alright. Thanks, guys. That's really helpful, and congrats again.

Christopher Anzalone: Thank you.

Operator: And our next question comes from the line of Patrick Trucchio with H. C. Wainwright.

Patrick Trucchio: Congrats on all the progress. I have a few follow-up questions. Just the first is just regarding, I'm wondering if the FDA has provided clarity on what level of pancreatitis evidence would be required for a future pancreatitis risk reduction claim, particularly in the high-risk SHTG patient population. And separately, wondering if there's been discussions around a potential pediatric pathway just given that FCS presents in childhood? And then just on the MAPT program. I'm wondering what level of CSF tau knockdown or biomarker response would you consider clear clinical proof of concept in humans just given I think you have greater than seventy-five percent knockdown in the NHP data?

Bruce Given: So the first one is less level of AP that we think the FDA is required to have it on the label. Yeah. You know, we have not discussed with the FDA specifically what it would take to get a claim per se. I'm not sure we've really felt that was necessary. I mean, I think physicians, you know, have no real question about the relationship of triglycerides to pancreatitis risk, especially now that it's been proven. And payers haven't seemed to be concerned about that either, at least in the US. So I'm not sure, you know, what the value of a claim would be. And, of course, at this point, it's untested.

You know, whether the agency, you know, would consider providing that, you know, that claim. I don't know that we've really thought of it as being necessary, Patrick, to be clear.

Christopher Anzalone: In FCS. Patrick, is your question on FHDG or FCS?

Patrick Trucchio: It's around actually the high-risk SHTG patient population.

Bruce Given: Yeah. But the answer is the same, I think. You know, we at least have not approached asking them, you know, when they give a claim, what it would take to get that claim. It's very possible that what they would require is something, you know, like Shasta five, but, you know, the Shasta five was really designed primarily, you know, on the possibility that the payers in countries outside the US might require a dedicated outcome study. So it was more payer-focused than it was regulatory-focused. And, you know, we know, we really were not committed one way or the other about whether it'd be submitted to regulators asking for a label change.

We were more interested really in protecting the possibility that there would be payers outside of the US that would require, you know, a specific proof of concept in a dedicated study. So we really haven't raised this with regulators, you know, anywhere on a global basis at this point.

Christopher Anzalone: You want to address the pediatric question?

Bruce Given: Oh, the pediatric question. We absolutely plan to do pediatric work at FCS. We have those plans in place. We have a pediatric plan in Europe, you know, and in the US. The only thing holding us back right now is just that we have to have a formulation so that we can use for weight-based dosing. And that's just, you know, we're in the process of getting that formulation put together so that we can go ahead and do those studies. But we're absolutely planning on doing that.

James Hamilton: In terms of what we're looking for based on the data, as you mentioned, at the tissue level, we were seeing seventy-five percent plus reductions. And similar reductions in the CSF in monkeys. I mean, we typically translate well from cynos into the clinic into humans. And I think based on some of the other data out there with the intrathecal intrathecally administered ASO, and they were able to achieve CSF reductions of about 50% to 60% and those CSF reductions corresponded to improvements in tau PET signals. So, you know, I think that's probably where we're aiming for in our clinical study is at least 50% to 60% reduction in the CSF.

That's what others have shown that seems to have translated into a meaningful tau PET signal.

Patrick Trucchio: Great. Thanks so much.

Operator: Thank you. Your next question comes from the line of Andrea Newkirk with Goldman Sachs.

Andrea Newkirk: Good afternoon. Thanks for taking the question. Maybe one more on the Rodemplo launch. Recognize it's only been about a week since the approval. But now that you have launched, just curious if you'd be willing to comment on your expectations for the cadence of the initial launch here in FCS and how you think it may be similar or different from that of the Trangosa launch, particularly in the context of the significant pricing differential that you have? Thank you so much.

Andy Davis: Happy to take that, Andrea. This is Andy. So we do have very high ambitions for the Rodemplo launch. Expected to be the best in class. And as you know, there are a number of reasons why we believe that to be the case. Largely around the attributes of Rodemplo that we do believe make it a special molecule in this category. We talked about obviously the significant and sustained TG reduction. We've talked about the reduced incidence of acute pancreatitis. But even more importantly, we hear a lot of positive feedback around the safety and tolerability profile. So no contraindications, no warnings, and no precautions.

And we do have a lot of physicians and patients who are enthusiastic about the once every three-month dosing regimen. So with those product attributes, we have very high ambitions for the launch of Rodemplo in FCS specifically.

Operator: Thank you. And our next question comes from the line of Mike Ulz with Morgan Stanley.

Mike Ulz: Good afternoon. Thanks for taking the question, and congratulations on all the progress as well. Maybe just a follow-up on the Shasta three and four studies. You mentioned adopting the modified Atlanta criteria. Just curious now that you've seen some more detail around the core studies, are you considering any sort of, you know, adjustments or fine-tuning to your studies going forward? Thanks.

Bruce Given: Other than adapting the ATLANTIC criteria, I think we're, you know, feeling pretty good about the design and, you know, it was negotiated with the FDA. I don't think we saw anything in core that, you know, would cause us to, you know, see a need to change anything else. There's nothing that comes to mind. You know, James, would you see it any differently? You don't look closely at this too.

James Hamilton: Yeah. I agree. It didn't inspire any changes in the protocol. So, yeah.

Mike Ulz: Great. Thank you.

Operator: Thank you. Our next question comes from the line of Madison Elsadi with B. Riley.

Madison Elsadi: Good afternoon. Thanks for taking our question. I wanted to ask about your neuromuscular franchise. Just given your integrin-targeted delivery mechanism, which, you know, one could assume may be safer and perhaps more targeted than a TFR-mediated approach. Should we expect DMPK knockdown and splice correction data comparable to kind of the pure benchmark levels? And, relatedly, wondering what dose do you anticipate observing really optimal biomarker activity? I believe previously, you said that even a low dose may be active. Thanks.

James Hamilton: Sure. Yeah. I think most of that will defer to Sarepta. Probably can't comment on the dose where we'd expect to see maximum knockdown. We don't know that yet. And so I would, you know, want to venture a guess there yet. In terms of the knockdown, I mean, I think that is probably a goal is to have something that looks at least similar to or equivalent to what others have shown for DMPK knockdown and splice correction with this platform.

Madison Elsadi: Got it. And then, if I may, are there any bile cells associated with hitting a certain threshold, or are the milestones largely related to regulatory progression?

James Hamilton: Yeah. Based only on regulatory and commercial, there are no sort of activity-based or PD-based milestones.

Madison Elsadi: Got it. Got it. Thanks.

Operator: And our last question comes from the line of Joseph Tome with TD Cowen.

Joseph Tome: Hi there. Good afternoon. Thank you for taking my question. Just another quick one on the dimer. Just curious based on your work in SHTG, what proportion of patients are already on an anti-PCSK9 treatment? Is this, you know, an under-treated population on both sides? And then can you give us an indication in terms of the triglyceride and LDL cutoffs that you're looking in patients enrolled into the early dimer study? Thank you.

James Hamilton: Sure. Yeah. I think based on the work that we've done, I mean, a lot of those patients may be on a statin, probably less so on fibrates, and very few of them on PCSK9 inhibitors. Actually, they're not that commonly used in that population. In terms of the cutoffs and the inclusion criteria, so we allow patients in that study with mixed hyperlipidemia or triglycerides up to 880. So it's a pretty high threshold, and they have to have either that non-HDL of 100 or an LDL greater than 70 to get into the study. So they have to have true mixed hyperlipidemia, both high triglycerides and high non-HDL or LDL cholesterol.

Joseph Tome: Thank you.

Operator: I'll now hand the call back over to President and CEO, Christopher Anzalone, for any closing remarks.

Christopher Anzalone: Thanks very much for joining us today. Again, thank you to Bruce, you know, for all he has brought to the company. He is reretiring. He is not going to be gone, however, and I do trust that he will still be around and helping us out going forward. So, again, thanks to Bruce and thanks to James for continued and ongoing leadership. Again, thank you all for joining us today, and I hope you have a pleasant Thanksgiving holiday.

Operator: Ladies and gentlemen, thank you for participating. This does conclude today's program, and you may now disconnect.